2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoring
2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2013
Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa
Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe TL, Bamber S, Moll AP, Friedland GH, Shah NS, Gandhi NR. Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa. PLOS ONE 2013, 8: e73975. PMID: 24040132, PMCID: PMC3765317, DOI: 10.1371/journal.pone.0073975.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisBaseline chest radiographSputum smear statusCulture conversionMajority of patientsCD4 countHilar lymphadenopathySmear statusPleural effusionSputum smearChest radiographsAntiretroviral therapy eraCulture conversion rateMedian CD4 countPercent of patientsChest radiograph findingsEnd of treatmentTherapy eraAdvanced immunodeficiencyCavitary diseaseRadiograph findingsHIV statusRadiographic featuresIndependent associationTreatment outcomes
2012
Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]
Brust J, Shah N, Scott M, Chaiyachati K, Lygizos M, van der Merwe T, Bamber S, Radebe Z, Loveday M, Moll A, Margot B, Lalloo U, Friedland G, Gandhi N. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 998-1004. PMID: 22668560, PMCID: PMC3390442, DOI: 10.5588/ijtld.11.0713.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAnti-HIV AgentsAntitubercular AgentsAttitude of Health PersonnelCaregiversCD4 Lymphocyte CountCoinfectionDelivery of Health Care, IntegratedFeasibility StudiesFemaleHealth Knowledge, Attitudes, PracticeHIV InfectionsHome Care ServicesHumansMaleMedication AdherenceOrganizational ObjectivesPatient Care TeamProgram DevelopmentProgram EvaluationRural Health ServicesSocial SupportSouth AfricaTime FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantViral LoadConceptsMultidrug-resistant tuberculosisHome-based treatmentHIV treatmentAdverse reactionsTreatment outcomesTreatment programHigh HIV prevalent settingsMDR-TB treatmentEscalation of careSevere adverse eventsHIV treatment programsHIV-prevalent settingsCommunity health workersCo-infection ratePatient treatment programTreatment modelPromising treatment modelNew treatment modelRural KwaZulu-NatalHIV-coMonthly culturesAdherence supportAdverse eventsClinical responseHIV outcomesA Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 150-157. PMID: 22395672, PMCID: PMC3360837, DOI: 10.1097/qai.0b013e318251aedd.Peer-Reviewed Original ResearchConceptsHIV-KSKing Edward VIII HospitalSymptomatic visceral diseaseActive antiretroviral therapyOpen-label trialTreatment-naive patientsTertiary referral centerAdministration of chemotherapyHAART armUrgent chemotherapyAntiretroviral therapyReferral centerVisceral diseaseTreat analysisKaposi's sarcomaHAARTChemotherapySaharan AfricaOptimal approachHIVLamivudinePatientsSarcomaStavudineNevirapine
2010
Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa.
Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, Gandhi NR, Friedland G, Shah NS. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. The International Journal Of Tuberculosis And Lung Disease 2010, 14: 1244-51. PMID: 20843414, PMCID: PMC3030274.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusXDR-TB diagnosisXDR-TBDrug-resistant tuberculosisPediatric wardImmunodeficiency virusRural South AfricaXDR-TB patientsXDR-TB treatmentActive antiretroviral therapySputum culture conversionNeuropsychiatric side effectsHospital pediatric wardInfection control policiesCulture conversionAntiretroviral therapyRadiographic improvementNosocomial transmissionOverlapping toxicitiesMicrobiologic dataHIV treatmentMedical recordsMicrobiologic diagnosisHIV therapyPrevious historyPharmacokinetics and Whole-Blood Bactericidal Activity against Mycobacterium tuberculosis of Single Doses of PNU-100480 in Healthy Volunteers
Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. Pharmacokinetics and Whole-Blood Bactericidal Activity against Mycobacterium tuberculosis of Single Doses of PNU-100480 in Healthy Volunteers. The Journal Of Infectious Diseases 2010, 202: 745-751. PMID: 20629533, DOI: 10.1086/655471.Peer-Reviewed Original ResearchConceptsWhole-blood bactericidal activityMean maximal concentrationPNU-100480Single dosesMinimum inhibitory concentrationHealthy volunteersBactericidal activityMycobacterium tuberculosisExperimental murine tuberculosisSingle ascending dosesSingle oral dosesDrug-resistant tuberculosisMaximal concentrationInhibitory concentrationAscending dosesMurine tuberculosisExposure of parentsOral dosesDaily dosesLog/dayLinezolidDrug concentrationsTuberculosisMycobactericidal activityDoses
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2008
Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life in HIV-Infected Individuals
Mannheimer SB, Wold N, Gardner EM, Telzak EE, Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G, AIDS T. Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life in HIV-Infected Individuals. Clinical Infectious Diseases 2008, 46: 941-945. PMID: 18279044, DOI: 10.1086/528859.Peer-Reviewed Original ResearchDifferential adherence to combination antiretroviral therapy is associated with virological failure with resistance
Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, MacArthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008, 22: 75-82. PMID: 18090394, PMCID: PMC2405889, DOI: 10.1097/qad.0b013e3282f366ff.Peer-Reviewed Original ResearchConceptsNon-nucleoside reverse transcriptase inhibitorInitial virological failureCombination antiretroviral therapyVirological failureAntiretroviral resistanceAntiretroviral therapyTreatment-naive HIV-1-infected individualsDifferential adherenceProspective clinical trial dataHIV-1-infected individualsMultivariate Cox regression analysisProtease inhibitorsTime-updated variablesCox regression analysisDisease-specific factorsReverse transcriptase inhibitorClinical trial dataMedication resistanceAntiretroviral medicationsRandomized trialsMonths 1Transcriptase inhibitorSame timepointsTrial dataSecondary analysis
2007
Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean changeAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory dataImplementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies
Friedland G, Harries A, Coetzee D. Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. The Journal Of Infectious Diseases 2007, 196: s114-s123. PMID: 17624820, DOI: 10.1086/518664.Peer-Reviewed Original ResearchConceptsTB/HIV service integrationHIV service integrationNeeds of patientsPublic health approachWorld Health OrganizationHIV diseaseNational TuberculosisHIV programsHIV interactionsInfection influenceHealth approachSuccessful outcomeTuberculosisDiseaseHealth OrganizationLarge national programProgram settingsSmall demonstration projectsMost settingsOutcomesImplementation of programsProgram collaborationNational programLarge populationService integrationManaging multiple and extensively drug-resistant tuberculosis and HIV
Padayatchi N, Friedland G. Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opinion On Pharmacotherapy 2007, 8: 1035-1037. PMID: 17516869, DOI: 10.1517/14656566.8.8.1035.Peer-Reviewed Original Research
2006
Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphineOpioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysiciansAdministration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntibiotics, AntitubercularBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV
2005
Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa
Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, Friedland GH, Scadden DT, Aboobaker J, Jordaan JP, Lalloo UG, Esterhuizen TM, Coovadia HM. Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS 2005, 19: 441-443. PMID: 15750399, DOI: 10.1097/01.aids.0000161775.36652.85.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyKaposi's sarcomaCopies/Generic antiretroviral therapyUndetectable viral loadActive antiretroviral therapyGeneric antiretroviral drugsAntiretroviral efficacyViral loadAntiretroviral drugsLog10 declineClinical experienceSarcomaTherapySaharan AfricaSub-Saharan AfricaHIVPatientsAIDSBaseline
2004
Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8. The Journal Of Infectious Diseases 2004, 191: 324-332. PMID: 15633090, DOI: 10.1086/427337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHerpesvirus 8, HumanHIV InfectionsHIV-1HumansMaleMiddle AgedMycobacterium tuberculosisReverse Transcriptase InhibitorsRNA, ViralSarcoma, KaposiTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsKaposi's sarcomaHIV-1Opportunistic infectionsViral loadAfrican patientsUndetectable HIV-1 RNA levelsCell countHIV-1 RNA levelsPlasma HIV-1 levelsHuman immunodeficiency virus (HIV) infectionHIV-1 subtype CKaplan-Meier survival analysisMycobacterium tuberculosisHIV-1 levelsImmunodeficiency virus infectionProportion of patientsTarget cell availabilityHuman herpesvirus 8Immune activationTreatment regimensSubtype CTherapeutic responseTreatment outcomesVirus infectionHerpesvirus 8